ELIXIRGEN THERAPEUTICS, INC.

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Description: Pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing genetic diseases; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing infectious diseases; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing cancers; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing age-related diseases; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding ribonucleoprotein constructs for gene editing being for the treatment of genetic disorders; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding ribonucleoprotein constructs for treating genetic disorders in the nature of telomere shortening; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for regenerative medicine in the nature of cell rejuvenation; Development of pharmaceutical products for others; pharmaceutical product quality testing and evaluation for others; research and development of pharmaceutical products for others; research and development of medical products for others; research and development of pharmaceuticals for the treatment of age-related diseases and cancer; pharmaceutical products development; pharmaceutical research services; pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; research and development in the field of medical products

Description: Dosage medium preparations, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases, cancer, and aging-related diseases; vaccines; regenerative medicine, namely, pharmaceuticals for cell rejuvenation

Description: Retail store services featuring pharmaceutical drugs and chemical preparations for cell and gene therapy; "THERAPEUTICS"

Description: Retail store services featuring pharmaceutical drugs and chemical preparations; retail store services featuring pharmaceutical drugs and chemical preparations for cell and gene therapy; "THERAPEUTICS"

Description: Class 5: Pharmaceutical drugs for the treatment of infectious diseases, cancer, and aging-related diseases; chemical preparations for medicinal purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases; chemical preparations for pharmaceutical purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases; preparations of organisms for medical purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases
Class 42: Research and development of vaccines and medicines; testing of pharmaceuticals; research in the field of pharmaceuticals

Description: Class 5: Pharmaceutical drugs for the treatment of infectious diseases, cancer, and aging-related diseases; chemical preparations for medicinal purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases; chemical preparations for pharmaceutical purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases; preparations of organisms for medical purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases
Class 42: Research and development of vaccines and medicines; testing of pharmaceuticals; research in the field of pharmaceuticals

Description: Pharmaceutical preparations and substances for the treatment of telomere-shortening diseases (e.g., dyskeratosis congenita, Fanconi anemia, idiopathic and pulmonary fibrosis), karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and pseudobulbar palsy), muscular diseases (e.g., Muscular atrophies, muscular growth, myopathy diseases, muscular disorders, muscular dystrophy, myositis, neuromuscular diseases, and sarcopenia), diseases related to the brain, diseases related to the spine, cancer; chemicals and chemical preparations for medical and pharmaceutical purposes for telomere-shortening diseases (e.g., dyskeratosis congenita, and Fanconi anemia), idiopathic pulmonary fibrosis, karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and pseudobulbar palsy), muscular diseases (e.g., Muscular atrophies, muscular growth, myopathy diseases, muscular disorders, muscular dystrophy, myositis, neuromuscular diseases, and sarcopenia), diseases related to the brain, diseases related to the spine, and cancers | Development of pharmaceutical products for others; product quality testing and evaluation for others; research and development of pharmaceutical products for others; research and development of medical products for others